

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**RECEIVED
PATENT & TRADEMARK
MAY 21 2004Applicants Docket Number:
USA V2001/0092 US CNTApplicants:
XU, et alSerial No.
10/696,527Filing Date:
September 29, 2003Title of Invention:
Timing and Duration of Administration of Adenosine A1/A2 Agonist for Cardioprotection**CERTIFICATE OF TRANSMISSION**I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at 703-872-9306, on

Date of Deposit 5/21/2004

Printed Name of Person Signing Certificate Paul Irvine

Signature

Total Number of Pages Sent: 25

Agent: Jiang Lin

Group Art Unit: 1617

Examiner: Travers, Russell

OFFICIAL

TO:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- | | |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>Supplemental Application Data Sheet</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Request for Submission of a Supplemental Application Data Sheet</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | <input type="checkbox"/> Other |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

MAY. 21. 2004 11:11AM

ROSS OEHLER

NO. 2563 P. 2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
XU, et al.

Examiner: Tarvers, Russell

Art Unit: 1617

Application No.: **10/696,527**

Filed: **October 29, 2003**

Title: **Timing and Duration of Administration of
Adenosine A1/A2 Agonist for
Cardioprotection**

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,
at (703) 872-9306, on

May 21, 2004
Date of Transmission

Signature

REQUEST FOR SUBMISSION OF A SUPPLEMENTAL APPLICATION DATA SHEET

Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the Supplemental Application Data Sheet for the above-identified application, submitted under rule 37 CFR 1.76(c).

The inventor Zhelong XU has a new address. It is now "405 Presque Isle Lane, Chapel Hill, NC 27514".

The Commissioner is hereby authorized to charge any fees which are required by this paper to Deposit Account 18-1982.

Respectfully submitted,


Jiang Lin, Reg. No. 51,065
Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

Aventis Docket No. USAV2001/0092 US CNT

APPLICATION DATA SHEET

Electronic Version v14

Stylesheet Version v14.0

Title of Invention	Timing Curation of Administration of Adenosine A1/A2 Agonist for Cardioprotection
Application Type: regular, utility Attorney Docket Number: USAV2001/0092USCNT	
Correspondence address: Customer Number: 05487 *05487*	
Continuing Data: This is a Continuation of WO application number US02/14228, filed 2002-05-03 , now Pending. This is a Non-Provisional of US application number 60/288,936, filed 2001-05-04 , now Expired.	
Priority Data: Doc.No: 0120124.3; Country - GB; Date: 2001-08-17 us-priority-claimed	
Inventors Information: <u>Inventor 1:</u> Applicant Authority Type: Inventor Citizenship: CN Given Name: Zhelong Family Name: XU City of Residence: Chapel Hill State of Residence: NC Country of Residence: US Address-1 of Mailing Address: 405 Presque Isle Lane Address-2 of Mailing Address:	

City of Mailing Address: Chapel Hill

State of Mailing Address: NC

Postal Code of Mailing Address: 27514

Country of Mailing Address: US

Phone:

Fax:

E-mail:

Inventor 2:

Applicant Authority Type: Inventor

Citizenship: US

Given Name: James

Middle Name: M.

Family Name: DOWNEY

City of Residence: Mobile

State of Residence: AL

Country of Residence: US

Address-1 of Mailing Address: 1220 Anchor Drive

Address-2 of Mailing Address:

City of Mailing Address: Mobile

State of Mailing Address: AL

Postal Code of Mailing Address: 36693

Country of Mailing Address: US

Phone:

Fax:

E-mail:

Attorney Information:

practitioner(s) at Customer Number:

05487

05487

as our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Assignee 1:

Organization Name: Aventis Pharmaceuticals Inc.
Address-1 of Mailing Address: 300 Somerset Corporate Boulevard
Address-2 of Mailing Address:
City of Mailing Address: Bridgewater
State of Mailing Address: NJ
Postal Code of Mailing Address: 08807-2854
Country of Mailing Address: US
Phone:
Fax:
E-mail: